Comparative Pharmacology
Head-to-head clinical analysis: AMITID versus NORPRAMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMITID versus NORPRAMIN.
AMITID vs NORPRAMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.
Norpramin (desipramine) is a tricyclic antidepressant (TCA) that primarily inhibits the reuptake of norepinephrine, and to a lesser extent serotonin, at the presynaptic neuronal membrane, thereby increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminergic, and alpha1-adrenergic blocking properties.
75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.
25 mg orally three times daily; may increase gradually to 150 mg/day in divided doses. Maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours; clinically, steady-state is reached within 2-3 days.
Terminal half-life: 18-34 hours (mean ~27 hours); clinical context: supports once-daily dosing, but steady-state requires 5-7 days.
Renal: 60-80% as metabolites, <5% unchanged; Biliary/Fecal: 20-30% as metabolites.
Primarily renal (70%) as metabolites and unchanged drug; biliary/fecal (30%) as metabolites.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant